NASDAQ: LTRN
Lantern Pharma Inc Stock Forecast, Predictions & Price Target

Analyst price target for LTRN

Based on 1 analyst offering 12 month price targets for Lantern Pharma Inc

Min Forecast
$25.00+703.86%
Avg Forecast
$25.00+703.86%
Max Forecast
$25.00+703.86%

Should I buy or sell LTRN stock?

Based on 1 analyst offering ratings for Lantern Pharma Inc.

Strong Buy
Strong Buy
1 analysts 100%
Buy
0 analysts 0%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although LTRN's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates LTRN as a "Sell". Stocks with a Zen Rating of Sell have had an average return of -4.50% per year. Learn More

Be the first to know when Wall Street analysts revise their LTRN stock forecasts and price targets.

LTRN stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-04-02

1 of 1

Forecast return on equity

Is LTRN forecast to generate an efficient return?

Company
N/A
Industry
153.19%
Market
81.87%

Forecast return on assets

Is LTRN forecast to generate an efficient return on assets?

Company
N/A
Industry
36.07%

LTRN earnings per share forecast

What is LTRN's earnings per share in the next 2 years based on estimates from 1 analyst?

Avg 1 year Forecast
-$1.86
Avg 2 year Forecast
-$1.14

LTRN vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LTRN$3.11$25.00+703.86%Strong Buy
IRD$0.74$8.00+979.62%Strong Buy
KLRS$6.61N/AN/A
CELU$1.52N/AN/A
XFOR$0.19$2.83+1,398.94%Strong Buy

Lantern Pharma Stock Forecast FAQ

Is Lantern Pharma Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: LTRN) stock is to Strong Buy LTRN stock.

Out of 1 analyst, 1 (100%) are recommending LTRN as a Strong Buy, 0 (0%) are recommending LTRN as a Buy, 0 (0%) are recommending LTRN as a Hold, 0 (0%) are recommending LTRN as a Sell, and 0 (0%) are recommending LTRN as a Strong Sell.

If you're new to stock investing, here's how to buy Lantern Pharma stock.

What is LTRN's earnings growth forecast for 2025-2026?

(NASDAQ: LTRN) Lantern Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 13.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 18.17%.

Lantern Pharma's earnings in 2025 is -$20,781,213.On average, 1 Wall Street analyst forecast LTRN's earnings for 2025 to be -$20,059,589, with the lowest LTRN earnings forecast at -$20,059,589, and the highest LTRN earnings forecast at -$20,059,589.

In 2026, LTRN is forecast to generate -$12,294,587 in earnings, with the lowest earnings forecast at -$12,294,587 and the highest earnings forecast at -$12,294,587.

What is LTRN's forecast return on equity (ROE) for 2025-2028?

(NASDAQ: LTRN) forecast ROE is N/A, which is considered weak.

What is LTRN's Price Target?

According to 1 Wall Street analyst that have issued a 1 year LTRN price target, the average LTRN price target is $25.00, with the highest LTRN stock price forecast at $25.00 and the lowest LTRN stock price forecast at $25.00.

The Wall Street analyst predicted that Lantern Pharma's share price could reach $25.00 by Apr 2, 2026. The average Lantern Pharma stock price prediction forecasts a potential upside of 703.86% from the current LTRN share price of $3.11.

What is LTRN's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: LTRN) Lantern Pharma's current Earnings Per Share (EPS) is -$1.93. On average, analysts forecast that LTRN's EPS will be -$1.86 for 2025, with the lowest EPS forecast at -$1.86, and the highest EPS forecast at -$1.86. In 2026, LTRN's EPS is forecast to hit -$1.14 (min: -$1.14, max: -$1.14).

What is LTRN's forecast return on assets (ROA) for 2025-2028?

(NASDAQ: LTRN) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 36.07%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.